RankingsPricing
  1. US-listed companies
  2. NEUROONE MEDICAL TECHNOLOGIES Corp
  3. Raw

NEUROONE MEDICAL TECHNOLOGIES CorpNMTC

Market cap
$35.8M
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022		Sep 30,
2023		Sep 30,
2024
Net loss-27,604-36,244-62,863-47,775--6,781,161-13,640,160-9,948,168-9,999,613-11,859,491-12,318,110
Amortization and depreciation------47,60980,748118,620199,266246,791
Amortization of deferred issuance costs----------101,329
Stock-based compensation---------11
Fair value change in warrant liability----------327,092
Private placement warrant issuance costs reclassed to financing activities----------127,659
Loss on disposal of fixed assets----------32,143-
Amortization of discounts and premiums on short-term investments--------11,47145,571-
Non-cash lease expense-----------113,534
Accounts receivable-------48,336-15,099-33,237176,636
Inventory-------98,287606,2511908,467
Prepaid expenses-----------47,285
Accounts payable---11,505--66,257-269,601-350,313515,438-247,18966,993
Accrued expenses, deferred revenue, operating lease and other liabilities----------1,225,31316,214
Net cash used in operating activities32,299-----5,395,957-3,425,302-8,602,826-7,519,534-12,886,874-11,011,840
Purchases of short-term investments--------31-
Purchases of property and equipment-----58,352122,42767,079275,226384,117120,197
Net cash (used in) provided by investing activities------123,352-122,427-67,079-3,244,7653-120,197
Proceeds from issuance of common stock in connection with private placement-----5----836,777
Proceeds from issuance of warrants in connection with private placement----------2
Proceeds from issuance of common stock in connection with at-the-market offering program----------5
Issuance costs attributed to common stock and warrants issued in private placement----------1,320
Issuance costs in connection with at-the-market offering program----------236,597
Deferred issuance costs in connection with at-the-market offering program----------20,000
Deferred issuance costs in connection with debt facility----------75,000
Share repurchases for the payment of employee taxes----------81,403
Net cash provided by financing activities46,150----67121277
Net decrease in cash and cash equivalents------431-2,837,836-3,862,451
Unpaid purchases of property and equipment------16,872----
Modification of right-of-use asset and associated lease liability----------199,385
Non-cash warrants issued in connection with debt facility----------53,124
Unpaid issuance costs in connection with private placement----------185,903
Unpaid deferred issuance costs---------4,63195,837